Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Understanding Evolving Therapeutic Strategies for Graft-Versus-Host Disease (Module 1: Diagnosis, Risk Assessment, and Staging; Module 2: Current and Emerging Therapeutic Strategies)

Access Activity

Overview / Abstract:


Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the skin, gastrointestinal tract, and liver. Chronic GVHD often presents during the first year following HSCT but may develop in subsequent years and most commonly affects the skin; however, involvement of other sites such as the liver, gastrointestinal tract, joints, fascia, and lungs can occur alone or concurrently. Some patients have overlap with chronic GVHD, which is characterized by one or more acute features and is associated with poor outcomes. The various clinical manifestations of acute and chronic GVHD may be detrimental to a patient’s quality of life. In recent years, advances in the management of other HSCT-related complications such as cytomegalovirus and invasive fungal infections have led to substantial reductions in mortality. However, despite intensive research, GVHD remains a challenge due to its heterogeneity and complex pathogenesis, as well as a lack of well-defined therapeutic targets.


Hematologist/oncologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with GVHD.


Upon completion of this activity, participants should be able to:

1.) Assess criteria to appropriately diagnose acute and chronic GVHD
2.) Assess criteria to appropriately stage and grade acute and chronic GVHD


Upon completion of this activity, participants should be able to:

1.) Differentiate prophylactic strategies for patients undergoing hematopoietic stem cell transplant at high risk for GVHD
2.) Apply emerging data and guideline recommendations in individualized treatment plans for patients with acute and chronic GVHD


Jan 28, 2022


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

0.25 CME/NCPD (module 1), 0.75 CME/NCPD (module 2), 0.7 contact hours of pharmacotherapy credit



Presenters / Authors / Faculty

Corey S. Cutler, MD, MPH, FRCPC
Medical Director, Adult Stem Cell Transplantation Program
Dana-Farber Cancer Institute

Activity Specialities / Related Topics

Transplant Medicine, Oncology / Cancer / Radiation Therapy, Hematology

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Incyte.

Keywords / Search Terms

i3 Health i3 Health, graft-versus-host disease, graft versus host disease, graft vs host disease, GVHD, CME, NCPD, free CME, free NCPD, CNE, free CNE, CE, free CE, ILNA points, MOC, oncology, transplant, HSCT Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map